Valneva SE
VALNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeValneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. At a $498.8M market cap, Valneva SE ranks as a small-cap company within healthcare. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Market Cap
$498.8M
Beta
1.26
P/E (TTM)
—
P/E (Fwd)
4.42
EPS (TTM)
$-2.10
EPS (Fwd)
$1.19
ROE
-117.9%
ROA
-16.7%
Cash
$121.5M
Total Debt
$210.2M
Free CF
-$42.5M
52W Change
-43.2%
Annual Financials
Cash vs Debt
Where VALN stands vs its 150-day and 200-day moving averages
As of the October 12, 2026 close, VALN finished 6.17% below its 150-day moving average ($6.16) and 18.48% below its 200-day moving average ($7.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VALN overbought or oversold?
At the October 12, 2026 close, VALN's RSI(14) was 29.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $121.5M in cash, though total debt stands at $210.2M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$42.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -117.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $361.3M to $174.7M.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing VALN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.